NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

February 03, 2006 13:21 ET

Nymox Recommended in Three Recent Independent Analyst Reports

NEW YORK--(CCNMatthews - Feb 3, 2006) -

Nymox Now Rated "Strong Speculative Buy" by Dutton Associates, "Buy" by Cohen Independent Research Group, and "Speculative Buy" by WallStreet Research

Three current independent analyst reports recommend Nymox Pharmaceutical Corporation (NASDAQ: NYMX). The most recent recommendation from WallStreet Research was written by Alan Stone on December 22, 2005. The "buy" recommendation from Cohen Independent Research Group was written on December 6, 2005. The "strong speculative buy" recommendation from Dutton Associates was written by Dr. William Prather on November 17, 2005.

The Dutton report states, "Based on the assumptions that Nymox will announce a marketing collaborator over the near term and will be in Phase III clinical trials next year at this time, and comparing the current value of Nymox to an average of comparable biopharmaceutical companies in Phase III trials, we arrive at our 12-month price target on the common shares of $6.25 and our rating of Strong Speculative Buy."

The WallStreet Research report states, "With no long-term debt and a low burn rate compared to industry standards, especially considering the number of marketed products and significant projects in the pipeline, the Company appears to be an excellent buying opportunity."

According to the Cohen Independent Research Group, "We continue to rate Nymox Pharmaceutical Corp a BUY, with a base price of $7.20. Primary catalysts in the near future are: 1) increased orders for NicAlert/TobacAlert tests; 2) completion of the Phase II for NX-1207, the BPH treatment; 3) tie-up with a large pharmaceuticals company for NX-1207, if Phase II results are positive; and 4) any agreement related to the marketing of NX-4720. Long-term catalysts include: 1) the initiation of Phase III trial for NX-1207; and 2) the approval and timing for launch of AlzheimAlert test kits in the U.S."

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

The above analyst reports contain disclaimers stated in each individual report, and also stated in Nymox's initial press releases on the issuance of the reports, which concern risks, uncertainties, and limitations of the reports. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information